Anthem Biosciences IPO: Your Comprehensive Guide to Allotment, GMP, and Listing Buzz!

Introduction: Unpacking the Buzz Around Anthem Biosciences IPO

Anthem Biosciences has emerged as a pivotal player within the biopharmaceutical sector, specifically carving a significant niche in the Contract Research, Development, and Manufacturing Organisation (CRDMO) space. The market has witnessed considerable excitement surrounding its Initial Public Offering (IPO), with public interest evident through trending searches on platforms like “X” and Google for terms such as “Anthem Biosciences IPO allotment date” and “Anthem Biosciences IPO GMP today.” This widespread attention underscores the perceived importance and potential of the offering.

This report aims to provide a clear, data-backed analysis, moving beyond the general market noise to offer essential insights into the IPO’s key details, its remarkable subscription status, the Grey Market Premium (GMP) trends, a comprehensive company profile, its financial performance, inherent strengths, and potential risks. The objective is to equip the public with accurate and actionable information, enabling a more informed understanding of this significant market event.

The performance of an IPO, particularly from a company operating in a high-growth sector like biopharmaceuticals, often serves as a barometer for broader economic sentiment and investor appetite for innovation. Anthem Biosciences, strategically positioned in the critical CRDMO segment, represents a compelling investment opportunity that has rightfully captured substantial market attention.

Anthem Biosciences IPO at a Glance: Key Dates & Essential Details

The Anthem Biosciences IPO presented a significant opportunity for investors, with its core parameters defining the offering. The bidding period for the IPO extended from July 14, 2025, to July 16, 2025. Shares were offered within a fixed price band of ₹540 to ₹570 per share, with the minimum application lot size for retail investors set at 26 shares. The total issue size amounted to ₹3,395 crore.

A critical aspect of this IPO is its nature: it is entirely an Offer for Sale (OFS). This means that the entire proceeds from the sale go to existing shareholders and promoters, rather than directly to Anthem Biosciences for its operational or expansion needs. For investors, this structure implies that their capital is not directly funding the company’s immediate business expansion or strategic initiatives. Instead, investment is placed on the company’s existing operational strength and its projected growth trajectory, which is expected to be achieved through internal accruals or future financing. While a complete OFS is not inherently negative, it directs the focus of investment analysis towards the company’s established profitability and self-funding capabilities rather than new capital deployment.

The finalization of the IPO allotment status is anticipated on July 17, 2025. Following this, Anthem Biosciences shares are slated for listing on both the BSE and NSE on July 21, 2025.

The following table provides a concise summary of these essential details:

This table serves as a central, easily scannable reference point, directly addressing key trending queries and allowing readers to rapidly grasp the essential mechanics and timeline of the IPO.

Subscription Status: A Phenomenal Investor Response

The Anthem Biosciences IPO witnessed an overwhelmingly positive response from investors, culminating in an impressive overall subscription of 63.86 times on the last day of the bidding process. This remarkable level of oversubscription serves as a strong indicator of robust investor confidence and significant market demand for the offering.

A granular view of participation across different investor segments reveals the intensity of demand:

• Qualified Institutional Buyers (QIBs): This segment demonstrated exceptional demand, with the QIB portion being oversubscribed a staggering 182.65 times. The exceptionally high QIB subscription is a powerful signal. Qualified Institutional Buyers typically undertake rigorous due diligence, possess deep market knowledge, and often have a longer investment horizon. Their overwhelming participation strongly suggests that Anthem Biosciences’ business model, financial health, and future growth potential have passed stringent institutional scrutiny. This institutional endorsement can significantly influence the sentiment of other investor categories, contributing to the overall oversubscription. High QIB subscription often correlates with a strong listing performance and sustained post-listing interest, as these large investors are more likely to hold their positions for the long term. It signals a robust validation of the IPO’s attractiveness beyond speculative interest.
• Non-Institutional Investors (NIIs): The NII portion also saw substantial oversubscription, being booked 42.35 times. This indicates considerable interest from high-net-worth individuals and corporate entities.
• Retail Investors: The retail portion, catering to individual investors, was subscribed a healthy 5.64 times, demonstrating considerable participation from the general public.
• Employee Portion: The dedicated employee portion was booked 6.59 times, reflecting internal confidence in the company.

The following table summarizes the final subscription status:

While the retail portion’s 5.64 times subscription is healthy, the overall subscription of nearly 64 times means the actual probability of securing an allotment for individual retail investors becomes very low. This transforms the allotment process into a lottery, where many interested applicants will inevitably miss out. This high oversubscription and low allotment probability for retail investors could lead to increased buying interest in the secondary market once the shares are listed. Those who were unable to secure shares in the IPO may look to purchase them post-listing, potentially contributing to a strong debut and sustained demand.

Decoding the Grey Market Premium (GMP): What Does it Signal?

The Grey Market Premium (GMP) serves as an unofficial indicator of investor demand and the potential listing price, traded in the unofficial market before the official listing. It is crucial to acknowledge its unofficial nature and inherent volatility, as it is not regulated by SEBI.

The Grey Market Premium (GMP) for Anthem Biosciences IPO firmed up to ₹123 as of July 15, 2025. This robust GMP suggests a potential listing premium of over 21% over the upper end of the IPO price band (₹570 + ₹123 = ₹693, implying a 21.58% premium). Earlier reports indicated a Day 2 GMP ranging between ₹116-121, suggesting an approximate 20% listing gain. The increase in GMP from earlier estimates reflects growing positive sentiment.

The following table illustrates the GMP trend:

The consistent and even increasing GMP, despite the relatively high valuation (P/E of ~70.5x), suggests that the market is willing to pay a premium for Anthem Biosciences. This indicates strong investor confidence, likely driven by the company’s robust business model, high growth trajectory, and its entrenched position in a niche market. The positive GMP reinforces the high subscription numbers, creating a positive cycle of demand. A strong GMP, when coupled with high subscription rates, often creates a positive feedback loop, attracting more speculative interest for listing gains and potentially leading to a robust debut on the official exchanges. It signals that market participants expect the stock to open significantly above its issue price.

The firm GMP directly impacts investor strategy. For those who secured an allotment, a strong GMP implies a healthy profit opportunity on listing day. For those who missed out, it suggests that entering the stock in the secondary market might come at a higher price, potentially reducing immediate returns. This dynamic fuels interest and volatility on listing day. The firm GMP sets high expectations for listing day. While unofficial, it often acts as a reliable precursor to a strong opening, making the IPO attractive for both short-term investors seeking quick profits and long-term investors willing to pay a premium for a quality business.

About Anthem Biosciences: Pioneering in the CRDMO Segment

Founded in 2006, Anthem Biosciences is a Bengaluru-based Contract Research, Development, and Manufacturing Organisation (CRDMO). The company operates in a highly specialized niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services.

Anthem Biosciences distinguishes itself as one of the few Indian CRDMOs possessing integrated capabilities across both small molecules (chemical-based drug substances) and large molecules (biologics), offering a comprehensive solution to clients. This strategic focus on the CRDMO segment, particularly its integrated capabilities spanning both small and large molecules, places it in a highly specialized, high-growth area of the pharmaceutical industry. The CRDMO model allows pharmaceutical and biotech companies to outsource complex, capital-intensive R&D and manufacturing processes, ensuring a consistent demand stream for Anthem’s services.

This niche segment suggests higher barriers to entry for competitors and potentially stronger pricing power for Anthem. This strategic positioning provides Anthem Biosciences with robust revenue visibility and a resilient business model, which largely explains the significant investor confidence observed in the IPO’s oversubscription. It underscores the company’s ability to capture value in a critical part of the drug development lifecycle.

The company employs a differentiated fee-for-service (FFS) model, primarily catering to small and mid-sized biotech firms globally, a segment often underserved by larger CRDMOs. Since its inception, Anthem has built a strong track record, having served over 675 clients and successfully completed more than 8,000 projects.

Anthem’s facilities adhere to stringent global quality standards, being cGMP-compliant and approved by major international regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The fact that Anthem’s facilities hold approvals from stringent global regulatory bodies is a substantial competitive advantage. Obtaining and maintaining these approvals is a highly rigorous, time-consuming, and capital-intensive process, creating a formidable barrier to entry for potential competitors.

These certifications are absolutely essential for any CRDMO aiming to serve international clients, particularly those in highly regulated pharmaceutical markets. This global regulatory compliance not only enhances Anthem’s reputation and trustworthiness but also significantly broadens its accessible market, allowing it to engage with a wider range of clients worldwide. This “moat” around its business contributes directly to its sustained profitability and supports its long-term growth trajectory by ensuring market access and client confidence.

Developmental and commercial manufacturing activities formed a significant portion of its business in Fiscal 2025, contributing 70.78% of its revenue from operations and 71.90% of the total number of projects undertaken.

Anthem Biosciences holds a leading position in fermentation capacity within India, boasting 142 kL, which is over six times larger than its next Indian competitor. The company has ambitious plans to further expand this capacity to 182 kL by mid-FY26. This strategic expansion of fermentation and synthesis capacities is aimed at meeting the growing global demand for complex biologics and speciality ingredients, positioning the company for sustained future growth. This combination of scalable infrastructure and global regulatory compliance positions Anthem Biosciences for sustained market leadership and accelerated revenue growth. It mitigates potential bottlenecks in meeting increasing demand and enhances the company’s credibility and attractiveness to international clients, thereby solidifying its long-term growth prospects.

Financial Performance: A Deep Dive into the Numbers

Anthem Biosciences has demonstrated robust financial performance in the most recent fiscal year, FY25. The company delivered the highest revenue growth among its peers in FY25, achieving an impressive 29.96% year-on-year increase. This strong top-line growth was accompanied by exceptional operational efficiency, as the company posted a top-tier EBITDA margin of 36.81%. For FY25, Anthem reported a net profit of ₹451 crore. The company also showcased efficient capital utilisation with robust return ratios, including a Return on Net Worth (RoNW) of 20.8% and a Return on Capital Employed (ROCE) of 26.88%. As of March 2025, the company’s net worth stood at ₹2,410 crore.

The following table summarizes these key financial highlights:

At the upper end of the IPO price band (₹570), Anthem Biosciences is valued at approximately ₹31,800 crore. This valuation translates to a Price-to-Earnings (P/E) ratio of around 70.5 times based on its FY25 earnings. While this P/E ratio is on the higher side when compared to some peers like Syngene (P/E ~51), it is broadly in line with or even lower than others, such as Divi’s Labs (P/E 83). Analysts largely justify this premium valuation based on the company’s significant scale, advanced technological edge, and consistent profitability within its niche.

The P/E ratio of ~70.5x is high, yet the available information explicitly states that analysts justify this valuation. This justification stems from Anthem’s “highest revenue growth (29.96%) in FY25 among peers” and its “top-tier EBITDA margin of 36.81%”, coupled with its “scale, technological edge, and consistent profitability”. This suggests that the market is not just looking at past earnings but is pricing in significant future growth potential and the company’s ability to maintain high margins in a specialized and growing segment. Investors are essentially paying for anticipated future earnings and the company’s strong competitive positioning. This implies that Anthem Biosciences must continue to deliver exceptional growth and maintain its profitability to sustain and further justify its valuation post-listing. Any slowdown in growth could put pressure on its stock price.

Furthermore, the consistently high EBITDA margin (36.81%) and robust return ratios (RoNW 20.8%, ROCE 26.88%) are strong indicators of exceptional operational efficiency and effective capital management. This is particularly crucial in a capital-intensive and research-driven industry like CRDMO, where managing costs, optimising processes, and maximising returns on significant investments are paramount for long-term success. High margins suggest a superior business model, potentially leveraging advanced technology, proprietary processes, or highly efficient operations that allow Anthem to convert a significant portion of its revenue into operating profit. This makes the company more resilient to economic fluctuations and more attractive to investors seeking sustainable profitability.

Strengths That Set Anthem Biosciences Apart

Anthem Biosciences possesses several key strengths that position it favorably within the competitive biopharmaceutical landscape:

• Strong Industry Position: The company operates in a highly specialised and high-growth CRDMO segment, distinguished by its integrated capabilities across both small and large molecules. This dual capability provides a broader market reach and competitive advantage.
• Robust Financials: Anthem has demonstrated exceptional financial performance, recording the highest revenue growth and maintaining top-tier EBITDA margins among its peers in FY25. This indicates strong operational efficiency and a healthy financial foundation.
• Technological Edge & Scale: Anthem boasts a leading fermentation capacity of 142 kL in India, which is six times larger than its nearest domestic competitor. Its continuous expansion plans further solidify its technological and scale advantages.
• Diversified Client Base & Experience: Having served over 675 clients and successfully completed more than 8,000 projects since its inception, Anthem demonstrates broad market acceptance and extensive experience in its field.
• Global Regulatory Approvals: The company’s facilities are cGMP-compliant and have received approvals from major global regulatory bodies, including the USFDA, ANVISA, TGA, and PMDA.³ This global compliance enhances its credibility and facilitates access to highly regulated international markets. The fact that Anthem’s facilities hold approvals from stringent global regulatory bodies is a significant competitive advantage. Obtaining and maintaining these approvals is a highly rigorous, time-consuming, and capital-intensive process, creating a formidable barrier to entry for potential competitors. These certifications are absolutely essential for any CRDMO aiming to serve international clients, particularly those in highly regulated pharmaceutical markets. This global regulatory compliance not only enhances Anthem’s reputation and trustworthiness but also significantly broadens its accessible market, allowing it to engage with a wider range of clients worldwide. This barrier to entry around its business contributes directly to its sustained profitability and supports its long-term growth trajectory by ensuring market access and client confidence.
• Differentiated Business Model: Its fee-for-service (FFS) model, specifically tailored to cater to the needs of small and mid-sized biotech firms globally, allows it to tap into a significant and growing market segment.
• Strong Brokerage Confidence: Leading brokerages, including Anand Rathi and Canara Bank Securities, have confidently assigned a ‘Subscribe’ rating to the Anthem Biosciences IPO, citing Anthem’s strong industry position, robust revenue visibility, and high-margin business model as key reasons.

Key Risks and Challenges to Consider

While Anthem Biosciences presents a compelling investment case, several risks and challenges warrant careful consideration:

• Heavy Competition: The CRDMO market is highly competitive and fragmented, with over 1,000–1,500 global players. This intense competition could put pressure on pricing and market share, potentially affecting profitability.
• Client Concentration: A significant portion of Anthem’s revenue, over 70%, is derived from just 5 clients. This high client concentration poses a substantial risk, as the loss or reduction of business from even one major client could severely impact the company’s financial performance. While the company has served over 675 clients and completed 8,000+ projects, indicating a broad client base, the revenue concentration suggests a dependence on a few large, potentially recurring, contracts. This risk needs to be carefully monitored by investors. While the current concentration is a concern, the broader client engagement suggests a potential for future diversification. Investors might look for strategic initiatives from the company post-listing to reduce this concentration over time.
• Constant Technology Investment: The drug development process is inherently capital-intensive, with the cost of developing a new drug often exceeding $1 billion. This necessitates continuous and substantial investment in cutting-edge R&D, technology, and infrastructure to remain competitive and relevant in a rapidly evolving scientific landscape.
• Talent Shortage: The CRDMO industry heavily relies on highly skilled scientific talent, including scientists, technicians, and PhDs. A persistent shortage of such specialised talent could pose challenges for talent acquisition, retention, and scaling operations, potentially impacting project timelines and quality.
• Offer for Sale (OFS) Nature: As previously highlighted, the IPO is a complete Offer for Sale, meaning the company itself will not receive any direct funds from the IPO proceeds to fuel its business growth, expansion plans, or debt reduction. This means the company must rely on internal accruals or future external financing for its growth initiatives.
• Longer Payment Cycles: Anthem Biosciences experiences longer payment collection cycles compared to its peers. This can strain working capital, impact liquidity, and potentially slow down operational efficiency. The challenge of taking longer to get paid directly impacts Anthem’s working capital cycle and cash flow. In a high-growth industry that requires continuous investment in capacity expansion and R&D, efficient working capital management is paramount. Slower collections can lead to increased reliance on internal accruals or external financing, potentially straining liquidity and hindering the pace of expansion. While Anthem boasts strong financials, this specific risk highlights a potential operational inefficiency that, if not effectively managed, could constrain the company’s ability to fund its ambitious growth plans and maintain its competitive edge.

Expert Opinions: Should You Subscribe?

Leading brokerages, including Anand Rathi and Canara Bank Securities, have confidently assigned a ‘Subscribe’ rating to the Anthem Biosciences IPO. Their positive rationale is firmly rooted in Anthem’s strong industry position within the high-growth CRDMO segment, its robust revenue visibility, and its consistently high-margin business model.

Despite the premium valuation (P/E of 70.5x), analysts largely believe it is justified. This justification stems from the company’s significant scale, its advanced technological edge, and its track record of consistent profitability. The IPO is seen as presenting a compelling long-term growth opportunity, primarily due to Anthem’s differentiated offering and its strategic positioning in the high-growth CRDMO segment. The initial hesitation observed on Day 1 of the IPO bidding quickly dissipated, replaced by strong market confidence, which was further reinforced by the firming Grey Market Premium (GMP).

The consensus view recommends applying for the IPO, particularly for long-term investors with a moderate to high-risk appetite, with a strong potential for significant listing gains. The consistent “Subscribe” ratings from multiple reputable brokerages and the explicit verdict that the IPO is “attractive for long-term investors” are highly significant, especially given the high P/E ratio. This indicates a broad market consensus among experts that Anthem Biosciences is a quality growth stock. It suggests that the market is looking beyond immediate earnings multiples and is instead valuing the company based on its substantial future potential in a critical and expanding sector.

This widespread positive sentiment from financial experts can instil considerable confidence in retail investors. However, it also implies that the stock’s future performance will be highly contingent on the company’s ability to consistently execute its growth strategies, maintain its competitive edge, and continue to deliver strong financial results to justify its premium valuation.

How to Check Your Anthem Biosciences IPO Allotment Status

For investors who participated in the Anthem Biosciences IPO, checking the allotment status is a crucial next step. This section provides practical, actionable information to facilitate this process.

The primary methods to check the allotment status are through the official websites of the stock exchanges and the IPO’s official registrar. Investors can check their allotment status on the official websites of the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange). Another reliable method is to check on the website of the IPO’s official registrar, which for Indian IPOs is typically Link Intime India Private Ltd or KFin Technologies Ltd.

A general step-by-step guide for checking the allotment status is as follows:

• Step 1: Visit the Portal: Navigate to the chosen website (either BSE, NSE, or the IPO registrar’s portal).
• Step 2: Select IPO: On the portal, locate and select “Anthem Biosciences IPO” from the dropdown list of active or recently closed IPOs.
• Step 3: Enter Details: Investors will typically be prompted to enter one of the following: their IPO Application Number, their Permanent Account Number (PAN), or their Demat Account number.
• Step 4: Submit: After entering the required details, click on the ‘Submit’ or ‘Search’ button to view the allotment status.

To help investors track the process, it is important to remember these critical dates:

• Allotment Date: The finalisation of allotment is scheduled for July 17, 2025.
• Initiation of Refunds: For those who did not receive an allotment, the initiation of refunds is scheduled for July 18, 2025.
• Credit of Shares to Demat Account: Successful allottees can expect their shares to be credited to their demat accounts by July 18, 2025.

Providing clear, step-by-step instructions on how to check allotment status directly addresses a primary concern for IPO applicants. By detailing the process and relevant dates, this report significantly reduces investor anxiety and improves the overall user experience during the post-application phase. This practical guidance makes the information a truly valuable resource for the target audience.

What to Expect on Listing Day: July 21, 2025

Anthem Biosciences shares are officially expected to make their debut on both the BSE and NSE on July 21, 2025. The stock’s performance on its listing day will be influenced by a confluence of factors that have shaped pre-market sentiment.

Key factors influencing listing performance include:

• Overwhelming Subscription: The exceptionally high oversubscription, particularly from Qualified Institutional Buyers (QIBs) at 182.65 times, is a strong fundamental indicator of robust demand and institutional confidence.
• Positive Grey Market Premium (GMP): The firm’s GMP of ₹123, suggesting a healthy listing premium of over 21%, creates positive pre-market sentiment and expectations, often acting as a reliable precursor to a strong opening.
• Broader Market Conditions: The overall sentiment and performance of the broader equity market on July 21, 2025, will also play a role in determining the stock’s opening and initial trading performance. A buoyant market can further amplify positive momentum.
• Analyst Confidence: The ‘Subscribe’ ratings from multiple brokerages reinforce the positive outlook and could encourage sustained buying interest from both institutional and retail investors.

Given these strong indicators – overwhelming investor demand, a healthy Grey Market Premium, and positive expert recommendations – a robust listing with significant gains over the issue price is highly probable. The combination of Anthem Biosciences’ strong underlying business fundamentals (high growth, top-tier margins, a strategic niche in CRDMO, and global regulatory approvals) and the overwhelming market demand creates a powerful synergy. This suggests that the anticipated strong listing is not merely driven by speculative interest but is significantly backed by fundamental analysis and institutional conviction. This strong confluence of positive factors suggests that the listing day might not just be characterised by short-term speculative gains but could also see sustained interest from long-term investors looking to acquire the stock. It positions Anthem Biosciences for a potentially strong debut and sustained market presence.

Investors who successfully received an allotment may consider booking profits on the listing day, while others with a longer-term investment horizon might choose to hold their shares, anticipating continued growth in the promising biopharmaceutical sector.

Conclusion: Anthem Biosciences – A Compelling Proposition

In summary, the Anthem Biosciences IPO has proven to be a highly anticipated and remarkably successful offering, marked by overwhelming subscription across all investor categories and a robust Grey Market Premium. This reflects strong investor confidence in a fundamentally sound company operating within the high-growth and critical Contract Research, Development, and Manufacturing Organisation (CRDMO) sector.

While the company’s valuation appears premium, market analysts and brokerages largely justify this based on Anthem Biosciences’ impressive financial performance, its established market leadership, unique integrated capabilities, and compelling long-term growth prospects. For investors with a moderate to high-risk appetite, the IPO presents an attractive opportunity, offering both potential for strong listing gains and a promising long-term investment horizon.

As with all investments in the securities market, it is crucial to remember that they are subject to market risks. Prospective investors should always conduct their own thorough due diligence and consider consulting with a qualified financial advisor before making any investment decisions. This ensures that choices align with individual financial goals and risk tolerance.

Works Cited & Credits

1. www.businesstoday.in, accessed July 17, 2025, https://www.businesstoday.in/markets/ipo-corner/story/anthem-biosciences-ipo-allotment-status-check-application-latest-gmp-listing-date-484987-2025-07-17#:~:text=The%20IPO%20of%20Bengaluru%2Dbased,lot%20size%20of%2026%20shares.
2. Anthem Biosciences Ltd IPO – Issue Date, Price, Lot Size, Analysis & Details – Bajaj Finserv, accessed July 17, 2025, https://www.bajajfinserv.in/investments/anthem-biosciences-limited-ipo
3. Anthem Biosciences IPO subscribed 2x on day 2; Check GMP, and other key details, accessed July 17, 2025, https://economictimes.indiatimes.com/markets/ipos/fpos/anthem-biosciences-ipo-sails-through-on-day-2-check-gmp-and-other-key-details/articleshow/122487638.cms
4. Anthem Biosciences IPO: Invest or Avoid? Check GMP, Subscription Status – INDmoney, accessed July 17, 2025, https://www.indmoney.com/blog/ipo/anthem-biosciences-ipo-analysis
5. Anthem Biosciences IPO Allotment Live: Anthem Biosciences public …, accessed July 17, 2025, https://www.moneycontrol.com/news/business/ipo/anthem-biosciences-ipo-allotment-status-live-updates-anthem-gmp-allotment-status-check-online-july-17-liveblog-13287589.html
6. Anthem Biosciences IPO day 3: Issue subscribed over 60 times …, accessed July 17, 2025, https://www.livemint.com/market/ipo/anthem-biosciences-ipo-day-3-issue-subscribed-over-60-times-check-gmp-subscription-status-and-other-details-11752668668083.html